Neuroendocrine Peptide Catestatin Reduces Alzheimer's Tau Pathology and Amyloid Through Adrenergic Inhibition | Research

The takeaway

Catestatin ameliorated tauopathy, amyloidogenesis, synaptic dysfunction, and neuroinflammation across AD, CBD, and PSP models through inhibition of adrenergic signaling.

Stress hormone → neurodegeneration
Catestatin reveals that adrenergic (stress hormone) signaling drives tau pathology — and blocking it with this natural peptide reduces neurodegeneration across three diseases

What the researchers found

CST ameliorated tauopathy, amyloidogenesis, synaptic dysfunction, and neuroinflammation in AD, CBD, and PSP models through adrenergic signaling inhibition — revealing catecholamine-tau pathology connection.

Why it matters

Tau pathology drives multiple neurodegenerative diseases with no effective treatment. Catestatin addresses tau through a novel mechanism (adrenergic inhibition) different from existing approaches.

How the study worked

In vitro and in vivo models of AD, CBD, and PSP treated with catestatin, with assessment of tau aggregation, amyloid pathology, synaptic markers, neuroinflammation, and adrenergic signaling.

What this study cannot tell us

Preclinical models. Catestatin delivery to brain needs optimization. Chronic adrenergic inhibition may have cardiovascular effects.

How to read the evidence

Multi-model preclinical study across three neurodegenerative diseases. Novel mechanistic insight.

When this study was published

Published in 2025.

The bigger picture

Catestatin connects two seemingly unrelated systems — stress hormones and neurodegenerative protein aggregation — opening an entirely new therapeutic approach to tauopathies.

Questions still open

Would catestatin cross the BBB sufficiently for clinical use?
Do beta-blockers (also adrenergic inhibitors) show similar tau reduction?
Could catestatin prevent tauopathy onset in at-risk individuals?

Common questions

How does stress relate to Alzheimer's?

This study shows stress hormones (catecholamines) actively drive the tau protein aggregation that causes Alzheimer's and related diseases. The natural peptide catestatin blocks this pathway.

Could reducing stress prevent Alzheimer's?

While lifestyle stress management is always good, this study suggests pharmacological adrenergic blockade (not just relaxation) could prevent the molecular damage that leads to tau-based neurodegeneration.

Read the original research

Catestatin ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.

bioRxiv : the preprint server for biology

View on PubMed ↗Publisher’s paper ↗

Citation

Jati, Suborno; Kal, Satadeepa; Munoz-Mayorga, Daniel; Tang, Kechun; Sahoo, Debashis; Chen, Xu; Mahata, Sushil K. (2026). Catestatin ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.. bioRxiv : the preprint server for biology. https://doi.org/10.64898/2026.01.04.697519